Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

November 04, 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

News Conference News ISC 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

February 08, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

October 24, 2023

Good Real-World Outcomes Seen With Next-Generation Carotid Stent

News Conference News LINC 2023

Good Real-World Outcomes Seen With Next-Generation Carotid Stent

June 06, 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

News Conference News SCAI 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

May 25, 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

March 28, 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

News Conference News ISC 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

February 11, 2022

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

News Conference News ACC 2020

PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery

Yael L. Maxwell

March 31, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.